Chuck Ence - 26 Jun 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Reporting relationship
CA and CO
Issuer ticker
RLMD
Reported as of
26 Jun 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
30 Jun 2025, 19:29:16 UTC
Prior SEC filing
20 May 2025
Next SEC filing
06 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Chuck Ence

Key filing fact

Chuck Ence filed Form 4 for RELMADA THERAPEUTICS, INC. (RLMD) on 30 Jun 2025.

Key facts

  • This page summarizes Chuck Ence's Form 4 filing for RELMADA THERAPEUTICS, INC. (RLMD).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 30 Jun 2025, 19:29.

Change

  • Previous filing in this sequence was filed on 20 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001697779 Primary reporting owner

Ence Chuck

Relationship
CA and CO
Address
C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES,
Signature
/s/ Chuck Ence
Signature date
30 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLMD transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+400,000
Change %
Price
$0.000000
Shares after
400,000
Date
26 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
400,000
Exercise price
$0.6700
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest in 16 equal quarterly installments commencing on September 26, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .